ADAM10 and head and neck cancer: Two of the targets, ADAM10 and AJUBA, with mutations and loss of heterozygosity occurring in 28% of human head and neck cancers, were shown to act as haploin‐sufficient tumor suppressor genes by promoting NOTCH pathway activation.[49] Moreover, the majority of screening hits were NOTCH target genes with potent tumor suppressive capability.